Log in

NASDAQ:APREAprea Therapeutics News Headlines

$30.99
-1.51 (-4.65 %)
(As of 04/5/2020 03:49 AM ET)
Add
Compare
Today's Range
$30.13
Now: $30.99
$32.52
50-Day Range
$31.65
MA: $34.57
$41.09
52-Week Range
$15.10
Now: $30.99
$53.11
Volume44,948 shs
Average Volume105,843 shs
Market Capitalization$652.65 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Aprea Therapeutics (NASDAQ APRE) News Headlines

Source:
DateHeadline
Have Insiders Been Buying Aprea Therapeutics, Inc. (NASDAQ:APRE) Shares This Year?Have Insiders Been Buying Aprea Therapeutics, Inc. (NASDAQ:APRE) Shares This Year?
finance.yahoo.com - April 2 at 6:40 AM
Aprea Therapeutics (NASDAQ:APRE) Stock Rating Reaffirmed by Royal Bank of CanadaAprea Therapeutics (NASDAQ:APRE) Stock Rating Reaffirmed by Royal Bank of Canada
www.americanbankingnews.com - March 29 at 11:06 PM
Zacks: Analysts Set $31.00 Price Target for Aprea Therapeutics (NASDAQ:APRE)Zacks: Analysts Set $31.00 Price Target for Aprea Therapeutics (NASDAQ:APRE)
www.americanbankingnews.com - March 29 at 10:22 PM
Aprea Therapeutics (NASDAQ:APRE) Price Target Increased to $36.00 by Analysts at Morgan StanleyAprea Therapeutics (NASDAQ:APRE) Price Target Increased to $36.00 by Analysts at Morgan Stanley
www.americanbankingnews.com - March 27 at 5:13 PM
Aprea Therapeutics (NASDAQ:APRE) Posts Quarterly  Earnings Results, Misses Estimates By $0.24 EPSAprea Therapeutics (NASDAQ:APRE) Posts Quarterly Earnings Results, Misses Estimates By $0.24 EPS
www.americanbankingnews.com - March 27 at 9:05 AM
BRIEF-Aprea Therapeutics Reports Q4 Loss Per Share $0.64BRIEF-Aprea Therapeutics Reports Q4 Loss Per Share $0.64
www.reuters.com - March 26 at 11:08 PM
Aprea Therapeutics EPS misses by $0.24Aprea Therapeutics EPS misses by $0.24
seekingalpha.com - March 26 at 1:06 PM
APRE.OQ - Aprea Therapeutics Inc Profile | ReutersAPRE.OQ - Aprea Therapeutics Inc Profile | Reuters
www.reuters.com - March 26 at 1:06 PM
Aprea Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate UpdateAprea Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
finance.yahoo.com - March 26 at 8:06 AM
Aprea Therapeutics (NASDAQ:APRE) Lock-Up Period To End  on March 31stAprea Therapeutics' (NASDAQ:APRE) Lock-Up Period To End on March 31st
www.americanbankingnews.com - March 24 at 1:04 AM
Zacks: Brokerages Set $26.67 Target Price for Aprea Therapeutics (NASDAQ:APRE)Zacks: Brokerages Set $26.67 Target Price for Aprea Therapeutics (NASDAQ:APRE)
www.americanbankingnews.com - March 13 at 4:59 PM
Aprea Therapeutics (NASDAQ:APRE) Short Interest Up 45.8% in FebruaryAprea Therapeutics (NASDAQ:APRE) Short Interest Up 45.8% in February
www.americanbankingnews.com - March 13 at 12:56 AM
Aprea Therapeutics, Inc. Common stock (APRE) Real-Time QuotesAprea Therapeutics, Inc. Common stock (APRE) Real-Time Quotes
www.nasdaq.com - February 12 at 10:24 PM
Aprea Therapeutics, Inc. Common stock (APRE) Press ReleasesAprea Therapeutics, Inc. Common stock (APRE) Press Releases
www.nasdaq.com - February 12 at 5:24 PM
Aprea Therapeutics, Inc. Common stock (APRE) After-Hours QuotesAprea Therapeutics, Inc. Common stock (APRE) After-Hours Quotes
www.nasdaq.com - February 12 at 5:24 PM
Aprea Therapeutics Receives Breakthrough Therapy Designation for APR-246Aprea Therapeutics Receives Breakthrough Therapy Designation for APR-246
www.fool.com - January 30 at 4:14 PM
Aprea Therapeutics nabs accelerated review status in U.S. for APR-246Aprea Therapeutics nabs accelerated review status in U.S. for APR-246
seekingalpha.com - January 30 at 12:17 PM
Aprea Therapeutics Receives FDA Breakthrough Therapy Designation for APR-246 in Combination with Azacitidine for the Treatment of Myelodysplastic Syndromes (MDS) with a TP53 MutationAprea Therapeutics Receives FDA Breakthrough Therapy Designation for APR-246 in Combination with Azacitidine for the Treatment of Myelodysplastic Syndromes (MDS) with a TP53 Mutation
finance.yahoo.com - January 30 at 12:17 PM
Aprea Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020Aprea Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020
finance.yahoo.com - January 9 at 3:43 PM
Were Hopeful That Aprea Therapeutics (NASDAQ:APRE) Will Use Its Cash WiselyWe're Hopeful That Aprea Therapeutics (NASDAQ:APRE) Will Use Its Cash Wisely
finance.yahoo.com - January 3 at 4:11 PM
We're Hopeful That Aprea Therapeutics (NASDAQ:APRE) Will Use Its Cash WiselyWe're Hopeful That Aprea Therapeutics (NASDAQ:APRE) Will Use Its Cash Wisely
finance.yahoo.com - January 3 at 6:52 AM
Recap and Update of Positive Data from Phase Ib/II Clinical Trials of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presented at the 2019 American Society of Hematology (ASH) Annual Meeting in OrlandoRecap and Update of Positive Data from Phase Ib/II Clinical Trials of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presented at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando
finance.yahoo.com - December 12 at 9:06 AM
Aprea adds to APR-246-stoked rally, shares up 17%Aprea adds to APR-246-stoked rally, shares up 17%
seekingalpha.com - December 11 at 5:38 PM
Aprea Therapeutics Presents Results From U.S. Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual Meeting in OrlandoAprea Therapeutics Presents Results From U.S. Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando
finance.yahoo.com - December 9 at 3:44 PM
Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual Meeting in OrlandoAprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando
finance.yahoo.com - December 9 at 3:44 PM
Aprea Therapeutics Reports Third Quarter 2019 Financial ResultsAprea Therapeutics Reports Third Quarter 2019 Financial Results
finance.yahoo.com - November 14 at 8:00 PM
RBC: 3 Stock Picks Set to Soar 30%+RBC: 3 Stock Picks Set to Soar 30%+
finance.yahoo.com - November 11 at 6:47 PM
Aprea Therapeutics to Present Data from U.S. Phase 1b/2 MDS/AML Trial and French Phase 1b/2 MDS/AML Trial at 61st American Society of Hematology Annual MeetingAprea Therapeutics to Present Data from U.S. Phase 1b/2 MDS/AML Trial and French Phase 1b/2 MDS/AML Trial at 61st American Society of Hematology Annual Meeting
finance.yahoo.com - November 6 at 10:26 AM
Aprea Therapeutics, Inc. Rings the Opening Bell in Celebration of its IPOAprea Therapeutics, Inc. Rings the Opening Bell in Celebration of its IPO
www.nasdaq.com - October 28 at 5:41 PM
Aprea Therapeutics Announces Pricing of Initial Public OfferingAprea Therapeutics Announces Pricing of Initial Public Offering
finance.yahoo.com - October 11 at 2:31 PM
Aprea Therapeutics' stock opens 3.1% above IPO price, then rises furtherAprea Therapeutics' stock opens 3.1% above IPO price, then rises further
finance.yahoo.com - October 11 at 2:31 PM
Aprea Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesAprea Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - October 11 at 2:31 PM
Large Amounts Of Insider Trading In Aprea Therapeutics Following IPOLarge Amounts Of Insider Trading In Aprea Therapeutics Following IPO
finance.yahoo.com - October 11 at 2:31 PM
This page was last updated on 4/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel